- Home
- DHF vs FENC Comparison
DHF vs FENC Comparison
Compare DHF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$7.86
Company Overview
Basic Information| Metric | DHF | FENC |
|---|---|---|
| Founded | 1998 | 1996 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 185.7M | 276.3M |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | DHF | FENC |
|---|---|---|
| Price | $2.48 | $7.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | ★ 451.1K | 184.5K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 7.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.06 | $4.68 |
| 52 Week High | $2.39 | $9.92 |
Technical Indicators
Market Signals| Indicator | DHF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 52.61 |
| Support Level | $2.46 | $7.43 |
| Resistance Level | $2.50 | $7.83 |
| Average True Range (ATR) | 0.03 | 0.28 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 21.43 | 81.06 |
Price Performance
Historical Comparison DHF
FENC
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.